Health and Healthcare
Celator Pharma Skyrockets on Breakthrough Trial Results
Published:
Last Updated:
Celator Pharmaceuticals Inc. (NASDAQ: CPXX) was far and away leading the bulls in Tuesday’s session following positive results from its late-stage clinical trial. The company announced positive results from its Phase 3 trial of Vyxeos Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML).
The trial met its primary endpoint, demonstrating a statistically significant improvement in overall survival. Data will be submitted for presentation at the American Society of Clinical Oncology 2016 Annual Meeting.
The median overall survival for patients treated with Vyxeos in the study was 9.56 months, compared to 5.95 months for patients receiving the standard of care regimen of cytarabine and daunorubicin known as 7+3.
The percentage of patients alive 12 months after randomization was 41.5% on the Vyxeos arm, compared to 27.6% on the 7+3 arm. The percentage of patients alive 24 months after randomization was 31.1% on the Vyxeos arm, compared to 12.3% on the 7+3 arm.
24/7 Wall St.Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
